Ovarian cancer in Western Australia (1982-1998): Trends in surgical intervention and relative survival

Gynecologic Oncology

Volumn 88, Issue 2, 2003, Pages 141-148

  Laurvick, Crystal L ^a   Semmens, James B ^a   Leung, Yee C ^b   Holman, C D'Arcy J ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b KING EDWARD MEMORIAL HOSPITAL   (Australia)

Author keywords

Ovarian cancer; Relative survival; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; DATA ANALYSIS; FEMALE; HEALTH INSURANCE; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OVARY CANCER; POISSON DISTRIBUTION; POPULATION RISK; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; SIDE EFFECT; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

EID: 0037331743     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(02)00095-1     Document Type: Article

References (41)

1. Cancer in Australia 1997: incidence and mortality data for 1997 and selected data for 1998 and 1999. AIHW Cat. No. CAN 10 (Cancer series No. 15) . 2000;AIHW, Canberra.
2. Kristensen G.B., Trope C. Epithelial ovarian carcinoma. Lancet. 349:(9045):1997;113-117.
3. Partridge E., Barnes M. Epithelial ovarian cancer: prevention, diagnosis, and treatment . CA Cancer J Clin. 49:1999;297-320.
4. Griffiths C.T. Surgery at the time of diagnosis in ovarian cancer. Blackledge G., Chan K.K. Management of ovarian cancer. 1986;60-75 Butterworth and Co, London.
5. Pecorelli S., Odicino F., Maisonneuve P., Creasman W.T., Shepherd J.H., Sideri M., et al. FIGO annual report on the results of treatment in gynaecological cancer: carcinoma of the ovary . J Epidemiol Biostat. 3:(1):1998;75-102.
6. Friedlander M.L. Prognostic factors in ovarian cancer. Semin Oncol. 25:(3):1998;305-314.
7. Stratton J.F., Tidy J.A., Paterson M.E.L. The surgical management of ovarian cancer [Review]. Cancer Treat Rev. 27:(2):2001;111-118.
8. Dauplat J., Le Bouedec G., Pomel C., Scherer C. Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol. 19:(1):2000;42-48.
9. Eisenkop S.M., Spirtos N.M. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol. 82:(3):2001;489-497.
10. Leibson C.L., Ballard D.J., Whisnant J.P., Melton L.J. 3rd. The compression of morbidity hypothesis: promise and pitfalls of using record-linked data bases to assess secular trends in morbidity and mortality . Milbank Q. 70:(1):1992;127-154.
11. Sibthorpe B., Kliewer E., Smith L. Record linkage in Australian epidemiological research: health benefits, privacy safeguards and future potential . Aust J Public Health. 19:(3):1995;250-256.
12. Semmens J.B., Platell C., Threlfall T.J., Holman C.D. A population-based study of the incidence, mortality and outcomes in patients following surgery for colorectal cancer in Western Australia. Aust N Z J Surg. 70:(1):2000;11-18.
13. Holman C.D., Bass A.J., Rouse I.L., Hobbs M.S. Population-based linkage of health records in Western Australia: development of a health services research linked database . Aust N Z J Public Health. 23:(5):1999;453-459.
14. ICD-O: international classification of diseases for oncology . 2nd ed. 1990;WHO, Geneva.
15. International Classification of Procedures in Medicine. 1978;WHO, Geneva.
16. Australian version of the International Classification of Disease, 9th revision, Clinical Modification. Procedure classification. Vol. 3:1995;National Coding Centre, Sydney.
17. 1999;SAS Institute Inc, Cary, NC.
18. Rothman K.J. Modern epidemiology. 1986;Little, Brown & Company, Boston.
19. Therneau T, Sicks R, Bergstralh E, Offord J. Expected survival based on hazard rates. Technical Report 52, Mayo Foundation; 1994.
20. Hakulinen T., Tenkanen L., Abeywickrama K., Paivarinta L. Testing equality of relative survival patterns based on aggregated data. Biometrics. 43:(2):1987;313-325.
21. Pfleiderer A. Is there any progress in the outcome of patients suffering from ovarian cancer? Treatment strategies since 1957. Gynecol Oncol. 83:(3):2001;451-456.
22. Grossi M., Quinn M.A., Thursfield V.J., Francis P.A., Rome R.M., Planner R.S., et al. Ovarian cancer: patterns of care in Victoria during 1993-1995 . Med J Aust. 177:2002;11-16.
23. Clayton R.D., Obermair A., Hammond I.G., Leung Y.C., McCartney A.J. The Western Australian experience of the use of en bloc resection of ovarian cancer with concomitant rectosigmoid colectomy. Gynecol Oncol. 84:2002;53-57.
24. Covens A.L. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol. 78:(3 Pt 1):2000;269-274.
25. Eisenkop S.M., Spirtos N.M. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol. 82:(3):2001;435-441.
26. Brun J.L., Feyler A., Chene G., Saurel J., Brun G., Hocke C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol. 78:(1):2000;21-27.
27. Australian Institute of Health and Welfare (AIHW). Interactive National Hospital Morbidity Data. In: Australian Institute of Health and Welfare; 2000.
28. Clarke-Pearson D.L., Chin N.O., DeLong E.R., Rice R., Creasman W.T. Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival. Gynecol Oncol. 26:(1):1987;11-18.
29. Venesmaa P., Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol. 79:(2):1992;168-172.
30. Ellis H., Moran B.J., Thompson J.N., Parker M.C., Wilson M.S., Menzies D., et al. Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study . Lancet. 353:(9163):1999;1476-1480.
31. Tamussino K.F., Lim P.C., Webb M.J., Lee R.A., Lesnick T.G. Gastrointestinal surgery in patients with ovarian cancer. Gynecol Oncol. 80:(1):2001;79-84.
32. Allen D.G., Coulter J. Survival of patients with epithelial ovarian cancer and the effect of lymphadenectomy in those with stage 3 disease. Aust N Z J Obstet Gynaecol. 39:(4):1999;420-424.
33. Epidemiology of cancer in South Australia: incidence, mortality and survival 1977 to 1999. Incidence and mortality (1999) analysed by type and geographical location. Twenty-three years of data . 2000;South Australian Cancer Registry, Epidemiology Branch, Adelaide.
34. Ingelman-Sundberg A. Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand. 50:1971;1-7.
35. Serow S.F., Scully R.E., Sobin L.H. 1973;WHO, Geneva.
36. Taylor H.C. Malignant and semimalignant tumors of the ovary. Surg Gynecol Obstet. 48:1929;204-230.
37. Bjorge T., Engeland A., Hansen S., Trope C.G. Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993. Int J Cancer. 75:(5):1998;663-670.
38. Semmens J.B., Lawrence-Brown M.M., Fletcher D.R., Rouse I.L., Holman C.D. The Quality of Surgical Care Project: a model to evaluate surgical outcomes in Western Australia using population-based record linkage. Aust N Z J Surg. 68:(6):1998;397-403.
39. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:(9306):2002;572-577.
40. Brown Jones M., Krutzsch H., Shu H., Zhao Y., Liotta L.A., Kohn E., et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics. 2:2002;76-84.
41. Welsh J.B., Zarrinkar P.P., Sapinoso L.M., Kern S.G., Behling C.A., Monk B.J., et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA. 98:(3):2001;1176-1181.